Table 3 Treatment and clinical outcomes of patients by age groups
|  | 18–64 years (n = 136) | ≥ 65 years (n = 139) | p-value |
|---|---|---|---|
Empirical antibiotics, n (%) | 133 (97.8) | 137 (98.6) | 0.760 |
Effective MRSA empiric therapy, n (%) | 19 (14.2) | 25 (18.3) | 0.374 |
Targeted MRSA treatment, n (%) | 108 (80.6) | 102 (73.4) | 0.515 |
Vancomycin | 103 (75.7) | 99 (71.2) | 0.397 |
Linezolid | 2 (1.5) | 1 (0.7) | 0.549 |
Vancomycin + Linezolid | 3 (2.2) | 2 (1.4) | 0.303 |
None | 28 (20.6) | 37 (26.6) | 0.239 |
Treatment duration, mean (SD)a days | 16.27 (18.1) | 11.65 (13.4) | 0.017* |
Appropriate treatment duration, n (%) | 102 (94.4) | 46 (43.4) | 0.005* |
Infectious disease team consult, n (%) | 45 (41.3) | 32 (30.5) | 0.100 |
Repeated blood cultures obtained, n (%) | 92 (67.6) | 73 (52.5) | 0.010* |
Persistent bacteremia, n (%) | 37 (27.2) | 35 (25.2) | 0.281 |
Recurrent bacteremia, n (%) | 12 (8.9) | 8 (5.8) | 0.422 |
Overall all-cause mortality, n (%) | 86 (63.2) | 115 (82.7) | < 0.001* |
In hospital mortality, n (%) | 39 (28.7) | 78 (56.1) | < 0.001* |
Early mortality (14 days), n (%) | 21 (15.4) | 44 (31.7) | 0.002* |
Mortality in 30 days, n (%) | 32 (23.5) | 67 (48.2) | < 0.001* |
Mortality in 180 days, n (%) | 61 (44.9) | 100 (71.9) | < 0.001* |